Calamos Advisors
DGX icon

Calamos Advisors’s Quest Diagnostics DGX Stock Holding History

Calamos Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.34M Buy
44,052
+546
+1% +$107K 0.03% 432
2026
Q1 		$8.53M Buy
+43,506
New +$8.45M 0.03% 445
2024
Q1 		– Sell
-65,031
Closed -$8.97M – 966
2023
Q4 		$8.97M Sell
65,031
-849
-1% -$112K 0.04% 418
2023
Q3 		$8.03M Hold
65,880
– – 0.04% 450
2023
Q2 		$9.26M Hold
65,880
– – 0.05% 446
2023
Q1 		$9.32M Sell
65,880
-8,235
-11% -$1.18M 0.05% 468
2022
Q4 		$11.6M Sell
74,115
-13,104
-15% -$1.88M 0.05% 423
2022
Q3 		$10.7M Hold
87,219
– – 0.05% 447
2022
Q2 		$11.6M Buy
87,219
+2,347
+3% +$320K 0.05% 442
2022
Q1 		$11.6M Buy
84,872
+11,312
+15% +$1.58M 0.04% 478
2021
Q4 		$12.7M Buy
73,560
+2,848
+4% +$433K 0.05% 414
2021
Q3 		$10.3M Buy
70,712
+6,239
+10% +$913K 0.04% 419
2021
Q2 		$8.51M Buy
64,473
+14,663
+29% +$1.92M 0.04% 443
2021
Q1 		$6.39M Buy
49,810
+1,539
+3% +$190K 0.03% 465
2020
Q4 		$5.75M Sell
48,271
-2,090
-4% -$255K 0.03% 468
2020
Q3 		$5.77M Sell
50,361
-4,420
-8% -$522K 0.04% 428
2020
Q2 		$6.24M Sell
54,781
-3,605
-6% -$382K 0.04% 400
2020
Q1 		$4.69M Sell
58,386
-6,288
-10% -$651K 0.04% 408
2019
Q4 		$6.91M Buy
64,674
+616
+1% +$64.2K 0.03% 451
2019
Q3 		$6.86M Buy
64,058
+5,557
+9% +$570K 0.04% 440
2019
Q2 		$5.96M Buy
58,501
+2,895
+5% +$278K 0.03% 476
2019
Q1 		$5M Buy
55,606
+532
+1% +$46.1K 0.03% 455
2018
Q4 		$4.59M Buy
55,074
+8,244
+18% +$773K 0.03% 460
2018
Q3 		$5.05M Buy
46,830
+2,969
+7% +$326K 0.03% 458
2018
Q2 		$4.82M Buy
43,861
+5,256
+14% +$548K 0.03% 445
2018
Q1 		$3.87M Buy
38,605
+1,826
+5% +$187K 0.03% 476
2017
Q4 		$3.62M Sell
36,779
-840
-2% -$79.6K 0.02% 458
2017
Q3 		$3.52M Sell
37,619
-820
-2% -$87.1K 0.03% 435
2017
Q2 		$4.27M Buy
38,439
+1,019
+3% +$108K 0.03% 411
2017
Q1 		$3.67M Sell
37,420
-82
-0.2% -$7.82K 0.03% 399
2016
Q4 		$3.45M Buy
37,502
+20,049
+115% +$1.73M 0.03% 399
2016
Q3 		$1.48M Buy
17,453
+15
+0.1% +$1.26K 0.01% 490
2016
Q2 		$1.42M Buy
17,438
+2,201
+14% +$168K 0.01% 498
2016
Q1 		$1.09M Buy
15,237
+951
+7% +$63.8K 0.01% 518
2015
Q4 		$1.02M Hold
14,286
– – 0.01% 524
2015
Q3 		$878K Buy
14,286
+5
+0% +$349 0.01% 548
2015
Q2 		$1.04M Sell
14,281
-806
-5% -$59.5K 0.01% 544
2015
Q1 		$1.16M Buy
15,087
+9
+0.1% +$645 0.01% 536
2014
Q4 		$1.01M Buy
15,078
+78
+0.5% +$4.92K 0.01% 542
2014
Q3 		$910K Hold
15,000
– – 0.01% 522
2014
Q2 		$880K Hold
15,000
– – 0.01% 534
2014
Q1 		$869K Hold
15,000
– – 0.01% 521
2013
Q4 		$803K Hold
15,000
– – 0.01% 527
2013
Q3 		$927K Hold
15,000
– – 0.01% 481
2013
Q2 		$909K Buy
+15,000
New +$894K 0.01% 463

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Calamos Advisors's DGX Position: Q2 2026 in Review

Calamos Advisors increased its Quest Diagnostics (DGX) stake by 1.3% in Q2 2026, buying an estimated $107K and bringing the position to 44,052 shares worth $9.34M. The position accounts for 0.03% of the portfolio, ranked #432.

Calamos Advisors first reported a position in DGX in Q2 2013 and has held it in 45 quarters since. The position peaked at $12.7M in Q4 2021. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Calamos Advisors held 44,052 shares of Quest Diagnostics worth $9.34M as of Q2 2026.
  • Calamos Advisors bought 546 Quest Diagnostics shares in Q2 2026, an estimated $107K.
  • Quest Diagnostics made up 0.03% of Calamos Advisors's portfolio in Q2 2026, its #432 holding.
  • Calamos Advisors first reported a position in Quest Diagnostics in Q2 2013 and has held it in 45 quarters since.
  • Calamos Advisors's Quest Diagnostics position peaked at $12.7M in Q4 2021.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.